| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT05362773) | MacroGenics | 2022-07-13 |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT04216524) | M.D. Anderson Cancer Center | 2020-05-29 |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant (NCT04317781) | M.D. Anderson Cancer Center | 2020-03-27 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (NCT03779854) | Fred Hutchinson Cancer Center | 2019-08-29 |
| Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. (NCT03974971) | Samsung Medical Center | 2019-04-30 |
| Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03485547) | Dana-Farber Cancer Institute | 2018-08-23 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN (NCT03386513) | AbbVie | 2018-01-02 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03113643) | Dana-Farber Cancer Institute | 2017-06-26 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553) | Mayo Clinic | 2017-05-17 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies (NCT02730312) | Xencor, Inc. | 2016-08-01 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT02159495) | City of Hope Medical Center | 2015-12-15 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985) | Fred Hutchinson Cancer Center | 2015-03-23 |
| Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) (NCT02859623) | Centre Hospitalier Universitaire de Besancon | 2014-01-01 |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT00397579) | University of Texas Southwestern Medical Center | 2013-05-01 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (NCT01231919) | National Cancer Institute (NCI) | 2011-01-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |